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Abstract
Introduction The rational design of targeted therapies for
acute myeloid leukemia (AML) requires the discovery of
novel protein pathways in the systems biology of a specific
AML subtype. We have shown that in the AML subtype
with translocation t(8;21), the leukemic fusion protein
AML1–ETO inhibits the function of transcription factors
PU.1 and C/EBPα via direct protein–protein interaction. In
addition, recently using proteomics, we have also shown
that the AML subtypes differ in their proteome, interac-
tome, and post-translational modifications.
Methods We, therefore, hypothesized that the systematic
identification of target proteins of AML1–ETO on a global
proteome-wide level will lead to novel insights into the systems
biology of t(8;21) AML on a post-genomic functional level.
Thus, 6 h after inducible expression of AML1–ETO, protein
expression changes were identified by two-dimensional gel
electrophoresis and subsequent mass spectrometry analysis.
Results Twenty-eight target proteins of AML1–ETO includ-
ing prohibitin, NM23, HSP27, and Annexin1 were identified
by MALDI-TOF mass spectrometry. AML1–ETO upregu-
lated the differentiation inhibitory factor NM23 protein
expression after 6 h, and the NM23 mRNA expression was
also elevated in t(8;21) AML patient samples in comparison
with normal bone marrow. AML1–ETO inhibited the ability
of C/EBP transcription factors to downregulate the NM23
promoter. These data suggest a model in which AML1–ETO
inhibits the C/EBP-induced downregulation of the NM23
promoter and thereby increases the protein level of differen-
tiation inhibitory factor NM23.
Conclusions Proteomic pathway discovery can identify
novel functional pathways in AML, such as the AML1–
ETO–C/EBP–NM23 pathway, as the main step towards a
systems biology and therapy of AML.
Keywords AML . Proteomics . AML1–ETO . NM23 .
C/EBP. Cancer biology
Introduction
The rational design of targeted therapies for cancer and
leukemia requires the discovery of novel target proteins and
protein pathways in cancer cells, and the determination of their
functional relevance in the systems biology of a specific cancer
type. Acute myeloid leukemia (AML) with translocation
t(8;21)(q22;22) is characterized by the fusion protein AML1–
ETO, which is produced by translocation of the AML1
(RUNX1/PEBPα/CBFA2) gene on chromosome 21 to the
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ETO (MTG8) gene on chromosome 8. This fusion protein
consists of the N terminus of AML1 (1–177 amino acids)
fused to the full length of ETO [1, 2]. Expression of AML1–
ETO is detected in 12% of all AML cases and 40% of the
FAB subtype M2-AML patients [3–5]. In murine AML
models, AML1–ETO alone is not sufficient to induce
leukemia [6]. However, in the presence of additional
mutations introduced by using a strong mutagen N-ethyl-N-
nitrosourea (ENU), 55% of the transgenic mice develop AML,
and the other 45% develop T-lymphoblastic leukemia [7]. In
another model, AML1–ETO induces AML-M2 resembling
leukemia in cooperation with an activated receptor tyrosine
kinase TEL/PDGFβR in all 19 mice transplanted [8]. Other
studies have shown that AML1–ETO can lead to malignant
transformation of fibroblasts and myeloid cells [9–11].
AML1–ETO promotes the expansion and self renewal
capacities of human CD34+ hematopoietic stem cells, the cell
type in which the translocation is physiologically found [12,
13]. AML1–ETO is reported to have dominant negative or
dominant positive effects on AML1 activity, thus disrupting
the normal function of AML1 in hematopoiesis [10, 14–18].
We have recently reported that AML1–ETO upregulates
c-Jun expression via the JNK signal transduction pathway,
which demonstrates another mechanism of AML1–ETO-
induced positive effects on its target proteins [19]. We have
previously shown that AML1–ETO blocks myeloid tran-
scription factor C/EBPα by downregulating its mRNA,
protein, and DNA binding activity in t(8;21) myeloid
leukemia [20], and inactivates the myeloid master regulator
PU.1 by direct protein–protein interaction in myeloid
differentiation [21]. Our group has routinely applied
proteomic approach to analyze proteomic profile of various
AML subtypes, target, and interacting protein partner
identification in AML and APL cells [22–26]. Because
AML1–ETO disrupts and blocks the normal function of
myeloid transcription factors and requires other cooperating
factors to induce leukemia, we hypothesized that the
systematic identification of AML1–ETO target proteins on
a global proteome-wide level might lead to novel insights
into the pathogenesis and systems biology of AML1–ETO-
induced leukemia on a post-genomic functional level.
Materials and Methods
Cell Culture Human myeloid cell line U937 stably transfected
with AML1–ETO cDNA under the control of human metal-
lothionein promoter in the expression vector pPC18 (U937Z/A-
E)was kindly provided byDr. P. G. Pelicci (Instituto Europeo di
Oncologia, Milan, Italy). Parental cell line U937 was purchased
from DSMZ (ACC5) and used as a control throughout this
study. A tet-off-inducible U937 cells stably transfected with
AML1–ETO under the control of tet-responsive transcriptional
repressor tTA (U937T/A-E) and U937 cells containing the
empty vector tTA (U937T) was kindly provided by Dr. D. E.
Zhang (Scripps Research Institute). These cell lines were
cultured as described previously [19].
Two-Dimensional Gel Electrophoresis To Identify AML1–
ETO Target Proteins U937Z/A-E cells were induced with
Zn for 6 or 12 h, and samples were lysed in urea lysis
buffer (7 M urea, 2 M thio-urea, 4% CHAPS, 50 mM
dithiothreital, 2.5 mM EDTA, and 2.5 mM EGTA). Lysed
cells were ultracentrifuged for 90 min at 50,000 rpm at
21°C. In the first dimension, 350 μl of lysed samples was
separated on Immobiline™ dry strip pH 3–10 (Amersham
Biosciences, Cat. 17-1234-01) by isoelectric focusing on
IPGPhor machine (Amersham) as recommended. The
separated protein strips were reduced in urea buffer
containing 2% DTE and alkylated in urea buffer containing
2.5% iodoacetamide. The strips were loaded and separated
on 12% SDS-PAGE in the second dimension. The gels
were stained with colloidal Coomassie blue stain (Sigma,
Cat. B-0770) as recommended. Differential expression
pattern of proteins in uninduced U937Z/A-E and Zn-
induced U937Z/A-E gels was done using the ProteomWea-
ver Software (Definiens). These protein spots were excised
and digested overnight with 50 ng trypsin in 50 mM
NH4HCO3, pH 8.0. Digested peptides were eluted in 70%
acetonitrile and lyophilized using speed vac. Peptides were
resuspended in 5 μl of 10% acetonitrile, 0.1% TFA, and
mixed 1:1 with 2,5-dihydroxybenzoic acid matrix solution.
Further, mass spectrometry was performed as described
previously [23, 26]. The probability-based Mowse score for
peptide mass fingerprinting (PMF) database search hits as
between 65 and 227; protein scores greater than 62 were
significant (p<0.05). Twenty-eight target proteins of
AML1–ETO were identified. Two-dimensional gel electro-
phoresis and mass spectrometry were performed from three
independent experiments, and only proteins identified in
each of those three experiments were considered to be
target proteins of AML1–ETO.
Western Blot Analysis U937Z/A-E cells were induced with
100 μM ZnSO4 for 6 h, lysed in RIPA buffer, and analyzed
for AML1–ETO expression by Western blot as described
before [19, 21]. Anti-ETO (Cat. sc9737), anti-NM23-H2
goat polyclonal antibody (sc14790), and anti-β-tubulin
rabbit polyclonal (Cat. sc9104) antibodies were purchased
from Santa Cruz, and anti-prohibitin antibody (Cat. MS-
261-P) was from NeoMarkers, and were used as recom-
mended and described earlier [19, 27].
Patient Samples and Affymetrix Patient samples were
referred to the Laboratory for Leukemia Diagnostics,
Department of Internal Medicine III, Hospital Grosshadern,
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for routine cytomorphologic and cytogenetic analyses. At
the time each AML patient was diagnosed, mononuclear
cells from the bone marrow aspirate with more than 90%
blast cells were purified by Ficoll gradient separation. Total
RNA was isolated and processed as described before [28].
Standard affymetrix software (Microarray Suite, Version
5.0) and the HG-U133A set of normalization controls were
used for data analysis (mask file online available, www.
affymetrix.com). As recommended by the manufacturer,
100 human maintenance genes served as a tool to normalize
and scale the data prior to performing data comparisons
[28]. Expression signal intensities are given as absolute
numbers. The error bars indicate the s.e.m.; n indicates the
number of patient samples analyzed in each subgroup.
AML patient samples included FAB M2 patients with
translocation t(8;21), M2 with normal karyotype (M2-NK),
M2 with complex karyotype (M2-CK), M3 with t(15;17),
M3 variants (M3v), M4eo inversion 16, t(11q23), AML
complex karyotype, AML normal karyotype, normal
karyotype with FLT+, and normal karyotype with MLL-
PTD+.
Electrophoretic Mobility Gel Shift and Luciferase
Promoter Assay
Electrophoretic mobility gel shift assay (EMSA) was
performed as previously described. For promoter assays
human kidney 293T cells were transfected using Lipofect-
AMINE reagent (Invitrogen) in 24 well plates as described
earlier [29, 30], and myeloid U937 and K562 cell lines
were transfected using the effectene kit (Qiagen) as
described before [31, 32]. The plasmid constructs used in
the transfection assays were NM23h1-luc promoter (kindly
gifted by Dr. Dirk Eick, GSF, Munich), human C/EBPα, C/
EBPβ C/EBPδ, and AML1–ETO plasmids, which have
been previously described [21, 30]. As an internal control
plasmid for cotransfection assays, the pRL null (pRLO)
construct driving the Renilla luciferase gene (Promega) was
used as described [33] earlier. Firefly luciferase and Renilla
luciferase activities were measured in Turner Designs
Luminometer using Dual Luciferase Reporter Assay Sys-
tem (Promega). Results are given as means+s.e.m. of three
independent experiments.
Results
Identification of AML1–ETO-Regulated Target Proteins by
2D Gel Electrophoresis and MALDI-TOF Mass Spectrome-
try For the purpose of identifying AML1–ETO-regulated
proteins, a myeloid cell line system was used where
AML1–ETO is stably transfected in U937 cells under Zn-
inducible metallothionein promoter (U937Z/A-E) or under
the tet-off-inducible promoter (U937T/A-E) [19, 27].
AML1–ETO protein expression is induced when Zn is
added in the medium (Fig. 1a, lane 5) or when tetracycline
is removed from the medium (Fig. 1b, lane 4). In vitro
translated AML1–ETO was used as a positive control
(Fig. 1a, b, lane 1). For identification of AML1–ETO target
proteins, AML1–ETO expression was induced in U937Z/
A-E cells with Zn for 6 or 12 h, cells were lysed in urea
lysis buffer, and proteins were separated by 2D gel
electrophoresis. The gels were stained with colloidal
Coomassie blue stain (Fig. 1c, d). After comparing
uninduced U937Z/A-E cells (gel not shown) with Zn-
induced U937Z/A-E cells (Fig. 2) using the ProteomWea-
ver software (Definiens), differentially expressed protein
spots (marked with arrows) were excised and digested with
trypsin. The proteins were identified by PMF generated by
MALDI-TOF mass spectrometry and MASCOT database
search (Tables 1 and 2). The probability-based Mowse
score for PMF database search hits were between 65 and
227, and protein scores greater than 62 were significant (p<
0.05). As a control, U937 cells were also treated with Zn,
lysed in urea lysis buffer, separated on 2D gels, and
compared with U937Z/A-E gels (data not shown). We were
able to identify new target proteins of AML1–ETO whose
function is not yet known, for example, cDNA clone
IMAGE 4104570, cDNA clone IMAGE 3905254, hypo-
thetical protein FLJ35908 fragment, and uncharacterized
hematopoietic stem/progenitor cells protein MDS032. We
also identified other promising target proteins of AML–
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Fig. 1 Western blot analysis for inducible AML1–ETO expression. a
U937Z/A-E cells were induced with 100 μM ZnSO4 for 6 h, lysed in
RIPA buffer, and analyzed for AML1–ETO expression by Western
blot. U937 cells were also induced and used as control. In vitro
translated AML1–ETO (lane 1) was used as a positive control. As
seen in lane 5, AML1–ETO expression is increased after Zn
induction. b U937T/A-E cells were induced by removing tetracycline
from the medium for 24, 48, 72, and 94 h. Cells were lysed in RIPA
buffer and blotted for AML1–ETO. U937T cells containing the empty
vector were used as a control. AML1–ETO expression level was
increased after 24 h of tet-off induction (lane 4) and was continuously
detectable even after 90 h of induction (lanes 5–7)
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isomerase A, prohibitin, thioredoxin peroxidase, etc.
(Tables 1 and 2). Concordant data were observed with both
the inducible cell lines.
NM 23 (nucleoside diphosphate kinase A) is a tumor
metastatic process-associated protein reported to be in-
volved in a variety of cellular processes such as cell
proliferation, differentiation and development, signal trans-
duction, and G protein-coupled receptor endocytosis [34].
In mouse myeloid leukemia M1 cells, NM23 was identified
as a differentiation inhibitory factor [35]. NM23 has been
previously shown to correlate with increased cell prolifer-
ation in leukemia patient samples and in the leukemic cell
line HL60 [36], and in addition, NM23 is expressed at
higher levels in CD34+ proliferating hematopoietic pro-
genitors than in the differentiating cells [37]. Another
isoform DR-NM23, which is highly homologous to the
NM23-H1 and NM23-H2 gene, was cloned from chronic
myelogenous leukemia blast crisis primary cells [38].
Overexpression of DR-NM23 inhibits granulocytic differ-
entiation and induces apoptosis in 32Dcl3 myeloid cells
[39]. NM23 inhibits the induction of differentiation of
mouse myeloid leukemia cells M1 and human erythroleu-
kemia cells HEL, KU812, and K562 [40–44]. The amount
of NM23-H1 mRNA and protein decreases during the
induced differentiation of promyelocytic leukemia cells
HL-60 by TPA or DMSO into monocytic or granulocytic
lineage, respectively [45]. Elevated serum levels of NM23
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Fig. 2 Two-dimensional gel
electrophoresis to identify
AML1–ETO target proteins.
U937Z/A-E cells were induced
with Zn for 6 or 12 h, and
samples were lysed in urea lysis
buffer, and lysates were sepa-
rated in one- and two-
dimensional gel electrophoresis
and were stained with colloidal
Coomassie blue stain (Sigma,
Cat. B-0770) to visualize the
protein spots. As a control,
U937 cells were also induced
with Zn, lysed in urea lysis
buffer, separated on 2D gels,
and compared with U937Z/A-E
gels (data not shown)
Table 1 AML1–ETO-regulated proteins identified 6 h after Zn induction
Description Acc. no. Mass (Da) Up/down
Homo sapiens cDNA clone IMAGE 4104570 gi11156428 30,383 Down
Homo sapiens cDNA clone IMAGE 3905254 gi10407098 34,977 Down
cDNA FLJ11534 FIS, clone HEMBA1002679 Q9HAJ5 71,672 Down
Phosphoglycerate kinase KIHUG 44,985 Down
Prohibitin I52690 29,843 Up
Uncharacterized hematopoietic stem/progenitor cells protein MDS032 Q9NZ43 29,440 Up
mRNA for DNA helicase Q1 BAA07200 74,392 Down
TRIP230 015154 228,116 Up
Nucleoside-diphosphate kinase-NM23-H1g A33386 17,309 Up
dUTP pyrophosphatase G02777 17,908 Down
HSP27 E980237 22,427 Up
HSTROPCR (Tropomyosin) CAA28258 28,185 Down
Identification of AML1–ETO target proteins by MALDI-TOF mass spectrometry. After comparing gels for uninduced U937Z/A-E (gel not
shown) and Zn-induced U937Z/A-E cells using the ProteomWeaver Software (Definiens), differentially expressed protein spots were excised,
digested with trypsin, and identified using mass spectrometry and MASCOT database search. A total of 28 target proteins of AML1–ETO (12
from 6 h and 16 from 12 h Zn-induced condition) are identified. Two-dimensional gel electrophoresis and mass spectrometry were performed
from three independent experiments, and only proteins identified in each of those three experiments were considered to be target proteins of
AML1–ETO
86 Clin Proteom (2010) 6:83–91
malignant lymphomas, and neuroblastma [43, 44, 46–51].
In another study, the cell surface expression of NM23-H1
and H2 was decreased during in vitro erythroid and
granulocytic differentiation [43, 46]. Tumor suppressor
p53, which is involved in the G1 cell cycle check point,
regulates NM23 differentially depending on the cell type.
p53 upregulates the expression of NM23-H1 at mRNA and
protein level in MCF7 and J7B cells; in contrast, p53
downregulates Nm23-H1 in RKO and H1299 cells [52].
Thus, differentiation inhibitory factor NM23 seems to be a
key factor in leukemogenesis. Therefore, we chose NM23
to further characterize its role in AML–ETO-mediated
leukemogenesis.
The Protein Level of NM23 Is Increased After AML1–ETO
Induction and NM23 mRNA Expression Is Elevated in
t(8;21)-AML Patient Samples To further confirm the
proteomics data, AML1–ETO expression was induced in
U937T/A-E cells, and the expression of NM23 protein was
analyzed by Western blotting. AML1–ETO increases the
NM23 protein level (Fig. 3a, lanes 3–5) in comparison with
empty vector U937T cells (Fig. 3a, lane 1) and U937T/A-E
cells at 0 h (Fig. 3a, lane 2). Since the NM23 expression is
decreased during induced differentiation of leukemic cell
lines MEG-01 and HL60 [36, 45], these data suggest that
one possible mechanism of AML1–ETO-induced leukemia
could be via the increase of NM23 protein level.
To rule out false positives, it was important to confirm
more than one target by an independent method. Therefore,
we analyzed the prohibitin expression by Western blotting
to further validate the proteomics data. Induction of
AML1–ETO expression increased the prohibitin protein
level (Fig. 3b, lane 4). We further analyzed the NM23
mRNA expression in AML patient samples (n=199) by
Affymetrix oligonucleotide microarrays (Fig. 4). NM23
expression was elevated in all AML patient subgroups
analyzed in comparison with normal bone marrow mono-
nuclear cells (Fig. 4a).
Furthermore, we also analyzed HSP27 mRNA ex-
pression in AML patients as another target and found
that HSP27 mRNA level was highly elevated in
comparison with normal bone marrow cells. (Fig. 4b).
These data correlate with the reports published by other
groups where NM23 expression is higher in AML patients
than in normal bone marrow. Taken together, our data
suggest that NM23 is a target of AML–ETO. It is
interesting to note that so far the molecular mechanism
of how NM23 expression is regulated in AML or how
NM23 blocks granulocytic differentiation is not known.
Most of the studies have focused on analyzing mRNA or
protein levels of NM23 in AML patient samples and
correlating it to prognosis. Therefore, further, we sought to
investigate the mechanism on how AML1–ETO might
regulate NM23.
Table 2 AML1–ETO-regulated proteins identified 12 h after Zn induction
Description Acc. no. Mass (Da) Up/down
Calreticulin precursor A37047 48,283 Up
Alpha enolase ENOA_HUMAN 47,350 Up
Alpha enolase ENOA_HUMAN 47,350 Up
Alpha enolase ENOA_HUMAN 47,350 Up
Glyceraldehyde-3-phosphate dehydrogenase CAA25833 36,202 Up
Glyceraldehyde-3-phosphate dehydrogenase CAA25833 36,202 Up
Annexin I LUHU 38,918 Up
Hypothetical protein FLJ35908 (fragment) Q8NA27 65,077 Up
Alpha-complex protein 1 S58529 37,987 Up
Proteasome alpha 1 subunit, isoform 2 AAH02577 29,822 Up
Triosephosphate isomerase TPIS_HUMAN 26,807 Up
Phosphoglycerate mutase PMHUYB 28,900 Up
Probable thioredoxin peroxidase A46711 22,324 Up
Triosephosphate isomerase TPIS_HUMAN 26,807 Up
Peptydil-prolyl-cis-trans isomerase A CYPH_HUMAN 18,098 Up
Glutathion S-transferase P1C human Q15690 23,583 Up
Identification of AML1–ETO target proteins by MALDI-TOF mass spectrometry. After comparing gels for uninduced U937Z/A-E (gel not
shown) and Zn-induced U937Z/A-E cells using the ProteomWeaver Software (Definiens), differentially expressed protein spots were excised,
digested with trypsin, and identified using mass spectrometry and MASCOT database search. A total of 28 target proteins of AML1–ETO (12
from 6 h and 16 from 12 h Zn-induced condition) are identified. Two-dimensional gel electrophoresis and mass spectrometry were performed
from three independent experiments, and only proteins identified in each of those three experiments were considered to be target proteins of
AML1–ETO
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AML1–ETO Upregulates NM23 by Blocking the Ability of
CCAAT Enhancer Binding Proteins (C/EBP) to Down-
regulate the NM23 promoter NM23 and AML1–ETO are
involved in a block of granulocytic differentiation [20, 39,
53], and C/EBPα induces granulocytic differentiation [54,
55]. We hypothesized that C/EBPs may downregulate
NM23 expression, and AML1–ETO might inhibit this
function in order to increase the protein level of NM23 as
seen in Fig. 3a. We, therefore, transiently transfected human
kidney 293T or myeloid U937 and K562 cells with
NM23h1-luc promoter and C/EBPα (Fig. 5a), C/EBPβ
(Fig. 5b), or C/EBPδ (Fig. 5c). Twenty-four-hour post-
transfection, the promoter-luciferase activity was mea-
sured, which shows that C/EBPα downregulated NM23
promoter twofold (Fig. 5a), C/EBPβ fourfold (Fig. 5b),
and C/EBPδ fivefold (Fig. 5c). When AML1–ETO was
cotransfected with C/EBPα, C/EBPβ, or C/EBPδ, the
downregulation of NM23 promoter by C/EBPs was
blocked. Next, we also performed EMSA where we used
GCSF receptor promoter as positive control (Fig. 5d, left
panel) for ivt C/EBPα and human NM23 promoter oligo
(Fig. 5d, right panel) as probe, which shows that C/EBPα
indeed binds and downregulates hNM23 promoter. To our
knowledge, this is the first report where we show that C/
EBP proteins downregulate the NM23 promoter, and these
data for the first time link AML1–ETO and C/EBP to
regulate NM23. As NM23 is overexpressed in AML and
blocks granulocytic differentiation, downregulation of
NM23 might be an important step to induce myeloid/
leukemic cell differentiation.
Discussion
The proteomic approach is being routinely applied to the
molecular analysis of various human diseases and in particular
cancers such as breast, bladder, colorectal, stomach cancers,
and so forth. However, few have been reported on the
systematic identification of protein profile changes under a











































































































































































































N = 199, AML patients
Fig. 4 NM23 mRNA expression is increased in AML patient
samples: a NM23 mRNA expression is increased in AML patient
samples (n=199) in comparison with normal bone marrow (nBM)
mononuclear cells (n=8). AML patient samples included FAB M2
patients with translocation t(8;21), M2 with normal karyotype (M2-
NK), M2 with complex karyotype (M2-CK), M3 with t(15;17), M3
variants (M3v), M4eo inversion 16, t(11q23), AML complex karyo-
type, AML normal karyotype, normal karyotype with FLT+, and
normal karyotype with MLL-PTD+. The error bars indicate the
s.e.m.; n the number of patient samples analyzed in each subgroup. b
HSP27 mRNA expression is also increased in AML patients which
further validates the proteomics data
a
U937T/A-E
















































Fig. 3 AML1–ETO upregulates the protein expression of NM23. a
U937T/A-E cells were induced by removing tetracycline from the
medium for 24, 48, and 72 h. Cells were lysed in RIPA lysis buffer;
80 μg protein was separated on 12% SDS-PAGE and blotted for
NM23 with anti-NM23-H2 goat polyclonal antibody (Santa Cruz, Cat.
sc14790). NM23 expression was upregulated in AML1–ETO-induced
cells (lanes 3–5) in comparison with empty vector U937T cells (lane
1) and U937T/A-E cells at 0 h (lane 2) of upper panel. The same blot
was stripped and probed for β-tubulin for loading control (lower
panel). b Western blot analysis for prohibitin from U937Z/A-E cells
using anti-prohibitin antibody shows prohibitin is upregulated in with
AML1–ETO expression after 6 h (upper panel). The same blot was
stripped and probed for β-tubulin for loading control (lower panel)
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spectrometry based proteomic approach to profile the changes
in the protein expression pattern of human myeloid leukemia
cells U937 with inducible AML1/ETO expression after 6 h.
Because the molecular mechanism of how AML1/ETO
induces leukemia phenotype is not clearly understood, it
could, therefore, facilitate the efforts to establish the molecular
mechanism for pathogenesis of acute myeloid leukemia. This
could further help to develop a more systematic approach for
prognosis and subsequent diagnosis of the AML M2 subtype
where AML/ETO is reported to be overexpressed. Our results
show that induced expression of AML1–ETO in U937A/E
Zn-inducible cell line drastically changes the protein profile.
We confirmed that NM23 is target of AML/ETO in Western
blotting, and further validated the upregulation of prohibitin
ruling out the possibility of identified protein being false
positives. Although others have also shown that NM23 is
target of AML/ETO, no one has thus far shown the biological
relevance of NM23 being a target of AML1/ETO. Using
microarray, we were able to show that NM23 is indeed
overexpressed in various AML patient samples as compared
with normal bone marrow from healthy volunteers. This
further strengthens our mass spectrometry and Western
blotting data of NM23 upregulation. Apart from NM23,
HSP27 another target from identified list was upregulated at
mRNA level in various AML samples. Although assessing
expression of some of the identified proteins as down-
regulated both at protein and mRNA level would had been
ideal, however, none of them were interesting and hence not
considered. Overexpression of NM23 in myeloid precursor
32Dcl3 cells blocks GCSF-induced granulocytic differentia-
tion [39] and its expression increases in proliferating
hematopoietic cells [36, 37], whereas overexpression of C/
EBPα leads to granulocytic differentiation [54, 55] and











Fig. 6 Model: AML1–ETO might block myeloid differentiation by
blocking the ability of C/EBP proteins to downregulate the NM23
promoter. Our data suggest that C/EBP proteins downregulate NM23,
which might be a prerequisite for normal cell growth and differenti-
ation. AML1–ETO blocks this downregulation, thereby increasing the
protein level of NM23, which might lead to a block in differentiation
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Fig. 5 AML1–ETO blocks the
C/EBP protein-mediated NM23
inhibition: Human kidney 293T
cells were transfected with
0.2 μg NM23h1-luc promoter
(provided by Dr. Dirk Eick,
GSF, Munich), 0.1 μg C/EBPα
(a), or 0.1 μg C/EBPβ (b) or
0.1 μg C/EBPδ (c) [30], and
0.2 μg AML1–ETO [21]. d
EMSA analysis using radiola-
beled probe and 6 μg of in vitro
translated C/EBPα (left panel)
showing binding of C/EBPα on
GCSF receptor promoter served
as positive control; subsequent-
ly, binding of human NM23
promoter was observed with
same ivt C/EBPα. Results are
representative of three separate
experiments
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AML1/ETO disrupts myeloid differentiation by inhibiting C/
EBPα, we hypothesized that C/EBPs may inhibit NM23
expression. Using luciferase promoter assay, we confirmed
that C/EBPs do inhibit NM23 expression, and this inhibition
was drastically overcome by cotransfection of AMl/ETO
with C/EBPs proteins. C/EBPβ and δ had more inhibitory
effect on NM23 promoter, which could be due to the
presence of variable protein complexes at the target NM23
promoter. In addition to luciferase assay, we also performed
EMSA using NM23 promoter, which shows that C/EBPα
indeed binds to NM23 promoter and could possibly mediate
its inhibitory action upon NM23 (Fig. 5d). Based on
luciferase promoter assays, we assume that other C/EBP
proteins, which were not included in the EMSA experiments,
could bind more efficiently to the NM23 promoter and
inhibit its expression. In AML patients, however, NM23
repression via C/EBPα is relieved due to functional
inactivation of C/EBPα, which leads to enhanced NM23
expression and subsequent leukemic pathophysiology.
Based on our data, we propose a hypothetical model
(Fig. 6) suggesting how AML1–ETO might block myeloid
differentiation by blocking the ability of C/EBP proteins to
downregulate the NM23 promoter. Our data suggest that C/
EBP proteins downregulate NM23, which might be a
prerequisite for normal cell growth and differentiation.
AML1–ETO blocks this downregulation, thereby increas-
ing the protein level of NM23, which might lead to a block
in differentiation and increase in cell proliferation. Thus,
proteomic pathway discovery can identify novel functional
pathways in AML, such as the AML1–ETO–C/EBP–NM23
pathway, as key step towards gaining insights in to the
AML systems biology and its therapeutics.
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